Tibet Duo Rui Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical preparations, intermediates and active pharmaceutical ingredients. The Company mainly has self-produced products such as Sodium Acetate Ringer Injection and agent products such as Amoxicillin Sodium and Clavulanate Potassium for Injection. The Company's products mainly include liquid therapy, emergency medication, pediatric medication, psychiatric medication, and analgesic medication. The Company mainly operates its businesses in the domestic market.

Employees

461

Sector

Pharmaceuticals

Calendar

10-29 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
30/09/26	CN¥63.17	-1.33%	609,200
29/09/26	CN¥64.02	+0.28%	679,200
28/09/26	CN¥63.84	-3.65%	897,600
24/09/26	CN¥66.26	+0.12%	1,114,800
23/09/26	CN¥66.18	-1.61%	937,800

End-of-day quote Shenzhen S.E.

More quotes

End-of-day quote Shenzhen S.E. 30/09/2026			5-day change	1st Jan Change
63.17 ^CNY	-1.33%		-4.55%	+5.87%

09-29	Certain A Shares of Tibet Duo Rui Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-SEP-2026.	CI
09-20	Tibet Duo Rui Pharmaceutical Co., Ltd.(XSEC:301075) added to S&P Global BMI Index	CI

Market Cap	5.05B 753M 663M 629M 567M 1.07B 72.24B 1.08B 7.52B 2.89B 36.93B 2.83B 2.77B 118B	P/E 2024	-22.7x	P/E 2025	-46.3x
Enterprise Value	5.38B 802M 706M 669M 604M 1.14B 76.91B 1.15B 8.01B 3.08B 39.32B 3.01B 2.95B 126B	EV / Sales 2024	6.46x	EV / Sales 2025	32.7x
Free-Float	29.49%	Yield 2024 *	-	Yield 2025	-

09-29	Certain A Shares of Tibet Duo Rui Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-SEP-2026.	CI
09-20	Tibet Duo Rui Pharmaceutical Co., Ltd.(XSEC:301075) added to S&P Global BMI Index	CI
08-25	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Hubei Duorui Pharmaceutical Co., Ltd. from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 77.3 million.	CI
08-25	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-28	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-23	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-22	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Hubei Hairuidi Pharmaceutical Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 2.4 million.	CI
04-22	Tibet Jiakang TImes Technology Development Co., Ltd. entered into an Equity Transfer Agreement to acquire 69% stake in Xiamen Ruitilian Pharmaceutical Technology Co., Ltd. from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 27.6 million.	CI
04-22	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Wuhan Duorui Industrial Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 5.1 million.	CI
02-26	Wang Qingtai and Cao Xiaobing completed the acquisition of an additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd.	CI
02-24	Trading in Tibet Duo Rui Pharmaceutical's shares to halt	RE
01-20	Wang Qingtai and Cao Xiaobing proposed to acquire additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 620 million.	CI
12-04	Wang Qingtai, Cui Zihao and Cao Xiaobing completed the acquisition of 29.99% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Zhoushan Qingchang Enterprise Management Partnership Enterprise (Limited Partnership) and Tibet Jiakang TImes Technology Development Co., Ltd.	CI

1 day	-1.33%
1 week	-4.55%
1 month	+9.29%
3 months	+10.81%
6 months	+1.56%
Current year	+5.87%

Tibet Duo Rui Pharmaceutical Co., Ltd. Share Price

Stocks

301075

CNE100004RW5

Pharmaceuticals

Valuation: Tibet Duo Rui Pharmaceutical Co., Ltd.

Chart: Tibet Duo Rui Pharmaceutical Co., Ltd.

Latest news: Tibet Duo Rui Pharmaceutical Co., Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: Tibet Duo Rui Pharmaceutical Co., Ltd.

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 week	63	66.83
1 month	55.13	69.74
Current year	44.55	98.29
1 year	40.91	98.29
3 years	12.6	98.29
5 years	12.6	98.29
10 years	12.6	98.29

Manager	Title	Age	Since
Yong Deng CEO	Chief Executive Officer	60	30/11/2018
Chao Li DFI	Director of Finance/CFO	47	30/04/2017
Fen Jin DFI	Director of Finance/CFO	46	30/11/2017

Director	Title	Age	Since
Yong Deng CHM	Chairman	60	30/11/2017
Shao Zhong Zhang BRD	Director/Board Member	70	20/02/2020
Qin Deng BRD	Director/Board Member	58	20/02/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TIBET DUO RUI PHARMACEUTICAL CO., LTD.	-1.33%	-4.55%	+57.61%	+127.97%	753M
ELI LILLY AND COMPANY	-2.33%	+0.53%	+51.65%	+115.42%	1,031B
JOHNSON & JOHNSON	-1.06%	-1.65%	+42.78%	+69.98%	638B
ABBVIE INC.	-0.65%	-1.32%	+12.98%	+75.49%	462B
MERCK & CO., INC.	-2.66%	-1.87%	+73.13%	+41.15%	359B
ROCHE HOLDING AG	-0.06%	-3.88%	+34.32%	+39.39%	335B
NOVARTIS AG	-0.79%	+2.01%	+19.82%	+27.79%	273B
ASTRAZENECA PLC	-1.19%	-1.21%	+9.82%	+10.61%	253B
AMGEN INC.	-0.50%	+3.80%	+49.37%	+56.84%	228B
GILEAD SCIENCES, INC.	-1.47%	-1.53%	+34.28%	+98.89%	185B
Average	-0.89%	-0.62%	+38.57%	+66.35%	376.46B
Weighted average by Cap.	-1.01%	-0.23%	+39.79%	+71.22%

	2024	2025
Net sales	241M 35.87M 31.59M 29.93M 27.02M 50.93M 3.44B 51.59M 358M 138M 1.76B 135M 132M 5.64B	154M 22.98M 20.24M 19.18M 17.31M 32.63M 2.2B 33.05M 229M 88.3M 1.13B 86.31M 84.42M 3.61B
Net income	-62.67M -9.34M -8.23M -7.79M -7.04M -13.26M -896M -13.43M -93.26M -35.89M -458M -35.08M -34.32M -1.47B	-102M -15.23M -13.41M -12.71M -11.47M -21.62M -1.46B -21.9M -152M -58.51M -747M -57.19M -55.95M -2.39B
Net Debt	135M 20.08M 17.68M 16.75M 15.12M 28.51M 1.93B 28.87M 200M 77.13M 984M 75.4M 73.75M 3.16B	327M 48.71M 42.89M 40.64M 36.69M 69.15M 4.67B 70.05M 486M 187M 2.39B 183M 179M 7.65B